2026 Q1 -tulosraportti
41 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
4,07%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 631 | - | - | ||
| 1 322 | - | - | ||
| 338 | - | - | ||
| 1 | - | - | ||
| 300 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
·5 t sittennovo nordisk fonden is Denmark's largest foundation and "supports projects that will improve people's lives, society and the planet". The foundation therefore has three main focus areas, which are very VERY broad. As a major private shareholder in Novo, I suggest that the foundation in the future focuses on: "Research into diseases such as diabetes, obesity, cardiovascular diseases and infectious diseases". Avoid that the foundation's idealism and public service hinder strong management of the core business itself (and ending up like e.g. coop dk).- ·6 t sittenRemember that novo doesn't just have a challenge selling expensive diabetes medicine in usa. They are actually researching to change the biological mechanisms that cause the disease. If they - hopefully - continue this research in, among other things, gene and stem cell therapy, they will reach a new level. Novo should tell us more about these visions (just call them strategic goals) and large investments.
·7 t sittennews yeessss : Novo Nordisk may possibly be on its way to getting yet another blockbuster drug in its portfolio. Morgan Stanley assesses this, before the Danish pharmaceutical giant is expected to present data from a phase 3 study with the drug Ziltivekimab later this year, in the third quarter, Bloomberg News writes. Analyst Thibault Boutherin anticipates that Ziltivekimab in the study will show a reduction in cardiovascular risk of more than 15 pct., and on that basis, he sees a potential for 3 bn. dollar in annual sales for the drug. "This could be an important step for Novo to start diversifying away from GLP-1," the American investment bank also concludes. Morgan Stanley also speculates that Ziltivekimab could reach an annual revenue level of 5 bn. dollar, if the drug also proves effective in other indications. Novo Nordisk acquired Ziltivekimab into its pipeline in connection with the acquisition of Corvidia Therapeutics for 725 mio. dollar in 2020, but with the possibility that the price could rise to 2,1 bn. dollar. A "blockbuster" in the pharmaceutical industry is a drug with sales of more than 1 bn. dollar per year.
·9 t sittenNovo Nordisk may possibly be on its way to getting yet another blockbuster drug in its portfolio. This is estimated by Morgan Stanley, before the Danish pharmaceutical giant is expected to present data from a phase 3 study with the drug Ziltivekimab later this year, in the third quarter, Bloomberg News writes. Analyst Thibault Boutherin anticipates that Ziltivekimab will show a reduction in cardiovascular risk of more than 15 pct. in the study, and on that basis, he sees a potential for 3 billion dollar in annual sales for the drug. "This could be an important step for Novo to start diversifying away from GLP-1," the American investment bank also concludes. Morgan Stanley also speculates that Ziltivekimab could reach an annual revenue level of 5 billion dollar if the drug also proves effective in other indications. Novo Nordisk acquired Ziltivekimab into its pipeline in connection with the acquisition of Corvidia Therapeutics for 725 million dollar in 2020, but with the possibility that the price could rise to 2.1 billion dollar. A "blockbuster" in the pharmaceutical industry is a drug with sales of more than 1 billion dollar per year.
·10 t sitten · MuokattuSo it's down to 282,50kr ⬇️ I wonder if it will come down to around 280 by close 🤔
·31 min sittenYes, they are a bit ridiculous. They think they can influence the price by writing in here. By trying to create uncertainty. Quite pathetic.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
41 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
4,07%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5 t sittennovo nordisk fonden is Denmark's largest foundation and "supports projects that will improve people's lives, society and the planet". The foundation therefore has three main focus areas, which are very VERY broad. As a major private shareholder in Novo, I suggest that the foundation in the future focuses on: "Research into diseases such as diabetes, obesity, cardiovascular diseases and infectious diseases". Avoid that the foundation's idealism and public service hinder strong management of the core business itself (and ending up like e.g. coop dk).
- ·6 t sittenRemember that novo doesn't just have a challenge selling expensive diabetes medicine in usa. They are actually researching to change the biological mechanisms that cause the disease. If they - hopefully - continue this research in, among other things, gene and stem cell therapy, they will reach a new level. Novo should tell us more about these visions (just call them strategic goals) and large investments.
- ·7 t sittennews yeessss : Novo Nordisk may possibly be on its way to getting yet another blockbuster drug in its portfolio. Morgan Stanley assesses this, before the Danish pharmaceutical giant is expected to present data from a phase 3 study with the drug Ziltivekimab later this year, in the third quarter, Bloomberg News writes. Analyst Thibault Boutherin anticipates that Ziltivekimab in the study will show a reduction in cardiovascular risk of more than 15 pct., and on that basis, he sees a potential for 3 bn. dollar in annual sales for the drug. "This could be an important step for Novo to start diversifying away from GLP-1," the American investment bank also concludes. Morgan Stanley also speculates that Ziltivekimab could reach an annual revenue level of 5 bn. dollar, if the drug also proves effective in other indications. Novo Nordisk acquired Ziltivekimab into its pipeline in connection with the acquisition of Corvidia Therapeutics for 725 mio. dollar in 2020, but with the possibility that the price could rise to 2,1 bn. dollar. A "blockbuster" in the pharmaceutical industry is a drug with sales of more than 1 bn. dollar per year.
- ·9 t sittenNovo Nordisk may possibly be on its way to getting yet another blockbuster drug in its portfolio. This is estimated by Morgan Stanley, before the Danish pharmaceutical giant is expected to present data from a phase 3 study with the drug Ziltivekimab later this year, in the third quarter, Bloomberg News writes. Analyst Thibault Boutherin anticipates that Ziltivekimab will show a reduction in cardiovascular risk of more than 15 pct. in the study, and on that basis, he sees a potential for 3 billion dollar in annual sales for the drug. "This could be an important step for Novo to start diversifying away from GLP-1," the American investment bank also concludes. Morgan Stanley also speculates that Ziltivekimab could reach an annual revenue level of 5 billion dollar if the drug also proves effective in other indications. Novo Nordisk acquired Ziltivekimab into its pipeline in connection with the acquisition of Corvidia Therapeutics for 725 million dollar in 2020, but with the possibility that the price could rise to 2.1 billion dollar. A "blockbuster" in the pharmaceutical industry is a drug with sales of more than 1 billion dollar per year.
- ·10 t sitten · MuokattuSo it's down to 282,50kr ⬇️ I wonder if it will come down to around 280 by close 🤔·31 min sittenYes, they are a bit ridiculous. They think they can influence the price by writing in here. By trying to create uncertainty. Quite pathetic.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 631 | - | - | ||
| 1 322 | - | - | ||
| 338 | - | - | ||
| 1 | - | - | ||
| 300 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
2026 Q1 -tulosraportti
41 päivää sitten
‧1 t 2 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
7,95 DKK/osake
Viimeisin osinko
4,07%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·5 t sittennovo nordisk fonden is Denmark's largest foundation and "supports projects that will improve people's lives, society and the planet". The foundation therefore has three main focus areas, which are very VERY broad. As a major private shareholder in Novo, I suggest that the foundation in the future focuses on: "Research into diseases such as diabetes, obesity, cardiovascular diseases and infectious diseases". Avoid that the foundation's idealism and public service hinder strong management of the core business itself (and ending up like e.g. coop dk).
- ·6 t sittenRemember that novo doesn't just have a challenge selling expensive diabetes medicine in usa. They are actually researching to change the biological mechanisms that cause the disease. If they - hopefully - continue this research in, among other things, gene and stem cell therapy, they will reach a new level. Novo should tell us more about these visions (just call them strategic goals) and large investments.
- ·7 t sittennews yeessss : Novo Nordisk may possibly be on its way to getting yet another blockbuster drug in its portfolio. Morgan Stanley assesses this, before the Danish pharmaceutical giant is expected to present data from a phase 3 study with the drug Ziltivekimab later this year, in the third quarter, Bloomberg News writes. Analyst Thibault Boutherin anticipates that Ziltivekimab in the study will show a reduction in cardiovascular risk of more than 15 pct., and on that basis, he sees a potential for 3 bn. dollar in annual sales for the drug. "This could be an important step for Novo to start diversifying away from GLP-1," the American investment bank also concludes. Morgan Stanley also speculates that Ziltivekimab could reach an annual revenue level of 5 bn. dollar, if the drug also proves effective in other indications. Novo Nordisk acquired Ziltivekimab into its pipeline in connection with the acquisition of Corvidia Therapeutics for 725 mio. dollar in 2020, but with the possibility that the price could rise to 2,1 bn. dollar. A "blockbuster" in the pharmaceutical industry is a drug with sales of more than 1 bn. dollar per year.
- ·9 t sittenNovo Nordisk may possibly be on its way to getting yet another blockbuster drug in its portfolio. This is estimated by Morgan Stanley, before the Danish pharmaceutical giant is expected to present data from a phase 3 study with the drug Ziltivekimab later this year, in the third quarter, Bloomberg News writes. Analyst Thibault Boutherin anticipates that Ziltivekimab will show a reduction in cardiovascular risk of more than 15 pct. in the study, and on that basis, he sees a potential for 3 billion dollar in annual sales for the drug. "This could be an important step for Novo to start diversifying away from GLP-1," the American investment bank also concludes. Morgan Stanley also speculates that Ziltivekimab could reach an annual revenue level of 5 billion dollar if the drug also proves effective in other indications. Novo Nordisk acquired Ziltivekimab into its pipeline in connection with the acquisition of Corvidia Therapeutics for 725 million dollar in 2020, but with the possibility that the price could rise to 2.1 billion dollar. A "blockbuster" in the pharmaceutical industry is a drug with sales of more than 1 billion dollar per year.
- ·10 t sitten · MuokattuSo it's down to 282,50kr ⬇️ I wonder if it will come down to around 280 by close 🤔·31 min sittenYes, they are a bit ridiculous. They think they can influence the price by writing in here. By trying to create uncertainty. Quite pathetic.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 631 | - | - | ||
| 1 322 | - | - | ||
| 338 | - | - | ||
| 1 | - | - | ||
| 300 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt